EUCTR2017-000084-32-NL进行中（未招募）1 期
A study to characterize the humoral and cellular response following simultaneous immunization with a neo-antigen (KLH) and a recall antigen (tetanus) in healthy volunteers
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Eligible subjects must meet all of the following inclusion criteria at screening:
- •1.Healthy male subjects, 18 to 45 years of age (inclusive). The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease following a detailed medical history and a complete physical examination including vital signs, laboratory measurements and 12-lead ECG;
- •2.Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum bodyweight of 50 kg;
- •3.Previous immunization with tetanus toxoid as reported by the subject;
- •4.Willing to give written informed consent and willing and able to comply with the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Eligible subjects must meet none of the following exclusion criteria at screening:
- •1.Any disease associated with immune system impairment, including auto-immune diseases, HIV, any confirmed history of severe allergic reaction and transplantation patients;
- •2.Known infection requiring antibiotic therapy within the last three months prior to the study
- •3.Previous known exposure to Immucothel® or KLH;
- •4.Any adverse immune reaction following immunization with tetanus toxoid;
- •5.Known allergy against Thiomersal®, which is a stabilizer in the tetanus toxoid immunization;
- •6.Received immunosuppressive or immunomodulatory medication within 30 days prior to enrollment or planned to use during the course of the study;
- •7.Use of medication (prescription or over-the-counter) within 21 days of the first study day, or less than 5 half-lives (whichever is longer), and during the course of the study;
- •8.Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year;
- •9.Previous participation in an investigational drug or device study involving the dosing of a biological targeted at any immune pathway within one year prior to screening;
- •10.Loss or donation of blood over 500 mL within three months prior to screening;
- •11.Any (medical) condition that would, in the opinion of the investigator, potentially compromise the safety or compliance of the subject or may preclude the subjects’ successful completion of the clinical trial.
- •12.History of Schistosomiasis (infection with Schistosoma parasite).
- •13.History or current nicotine use in access of 5 cigarettes per day, or unable not to smoke during the course of the study, defined as between the screening visit and the final visit.
- •14.Tetanus toxoid immunization within the last 10 years before study participation
研究者
相似试验
已完成
4 期
A study to characterize the humoral and cellular response following simultaneous immunization with a neo-antigen (KLH) and a recall antigen (tetanus) in healthy volunteersNL-OMON45727Centre for Human Drug Research15
进行中（未招募）
1 期
A study of immunity for chickenpox and measles in childhood cancer patients.This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated immunity specifically targeted for varicella and measles, during and after treatment for childhood cancer. We also want to investigate vaccin response for varicella and measles.EUCTR2019-004541-33-SEVästra Götalandsregionen160
尚未招募
不适用
Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib)kidney cancer10038363GISTNL-OMON32710niversitair Medisch Centrum Sint Radboud75
进行中（未招募）
不适用
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) - mgus-vacc responsMonoclonal Gammopathy of Undetermined significanceEUCTR2010-022693-14-NLuniversity medical centre groningen
已完成
不适用
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)Monoclonal gammopathy of undetermined significanceMGUS10035227NL-OMON34204niversitair Medisch Centrum Groningen122